扶正化瘤方联合吉西他滨和顺铂治疗转移性三阴性乳腺癌的临床观察

Efficacy of Fuzheng Hualiu decoction combined with gemcitabine and cisplatin for metastatic triple negative breast cancer

目的观察扶正化瘤方联合吉西他滨与顺铂在转移性三阴性乳腺癌中的临床效果。方法选取2012年1月至2016年12月间南京中医药大学第一附属医院收治的68例转移性三阴性乳腺癌患者,采用随机数表法分为研究组与对照组,每组34例。对照组采用吉西他滨联合顺铂治疗,研究组在对照组治疗基础上辅以扶正化瘤方治疗,观察两组患者临床效果、治疗前后血清肿瘤标志物水平及不良反应。结果研究组患者临床有效率为44.1%,临床控制率为82.4%,对照组治疗有效率为35.3%,控制率为61.8%,两组相比,差异均有统计学意义(均P<0.05)。治疗后研究组患者癌胚抗原(CEA)、糖类抗原CA15-3和CA125浓度分别为(5.2±2.5)μg/ml、(35.2±14.1)IU/ml和(40.3±18.5)IU/ml,对照组患者分别为(7.8±3.6)μg/ml、(52.2±11.2)IU/ml和(61.3±21.3)IU/ml,两组相比,差异均有统计学意义(均P<0.05)。研究组患者治疗后KPS评分为(88.8±6.1)分,对照组为(78.8±5.8)分,两组相比,差异有统计学意义(P<0.05)。两组患者治疗过程中,中性粒细胞减少、血小板减少、恶心、呕吐及脱发等不良反应发生率比较,差异均无统计学意义(均P>0.05)。结论扶正化瘤方联合吉西他滨与顺铂治疗转移性三阴性乳腺癌效果好,安全性高,值得临床推广。

Objective To explore the clinical efficacy of Fuzheng Hualiu decoction combined with gemcitabine and eisplatin for metastatic triple negative breast cancer. Methods From January 2012 to De- cember 2016, 68 patients with metastatic triple negative breast cancer treated at First Clinical Medical Col- lege of Nanjing University of Chinese Medicine were selected. They were randomly divided into a study group and a control group with 34 in each group using a random number table. Fuzheng Hualiu decoction was added to gemeitabine and cisplatin in the study group and the control group was only given gemeitabineand cisplatin. After 2 cycles, the clinical efficacy, the changes of serum tumor markers before and after treatment and adverse reactions were observed. Results The efficacy rate was 44. 1% and the control rate was 82.4% for the study group, and the efficacy rate was 35.3% and the control rate was 61.8% for the control group （ P 〈 0. 05）. After the treatment, concentration of carcinoembryonic antigen （ CEA）, cancer antigen 15-3 （CA15-3） and cancer antigen 125 （CA125） was （5.2±2.5）μg/ml、（35.2±14.1）IU/ml和（40.3±18.5）IU/ml, respectively for the study group and （7. 8 ±3.6） μg/ml, （52. 2 ± 11.2） μg/ml and （ 61.3 ±21.3 ） μg/ml, respectively for the control group （ P 〈 0. 05 ）. KPS score was （ 88.8 ±6. 1 ） for the study group and （78.8 ±5.8 ） for the control group （ P 〈 0. 05 ）. No significant difference was noted in the incidence of adverse reactions including neutrophilic neutropenia, thrombocytopenia, nausea, vomiting and hair loss （ P 〉 0. 05 ）. Conclusion Fuzheng Hualiu decoction combined with gemcitabine and cisplatin has good efficacy and safety in treating metastatic triple negative breast cancer, which is worthy of clinical promotmn.